Meenhard Herlyn

发表

Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

Eytan Ruppin, Zhi Wei, Sanna Madan, 2018, Nature Medicine.

Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness.

Yingdong Zhao, Richard Simon, Paul H Duray, 2002, Cancer research.

Abstract 659: Overexpression of TPX2 accelerates cell cycle progression in melanoma and is an indicator of response to Aurora A kinase inhibitors

Bin Li, Meenhard Herlyn, M. Herlyn, 2010 .

Axis of evil: molecular mechanisms of cancer metastasis

Meenhard Herlyn, M. Herlyn, Thomas Bogenrieder, 2003, Oncogene.

B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma

Johannes Griss, Christoph Bock, Martin Simon, 2019, Nature Communications.

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance

Johannes Griss, Zhi Wei, Jie Zhang, 2017, Nature Communications.

Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion.

Eric Brown, Meenhard Herlyn, M. Herlyn, 2005, The American journal of pathology.

Tumors as elusive targets of T-cell-based active immunotherapy.

Soldano Ferrone, Francesco M Marincola, Meenhard Herlyn, 2003, Trends in immunology.

Defining the Conditions for the Generation of Melanocytes from Human Embryonic Stem Cells

Xiaowei Xu, Meenhard Herlyn, M. Herlyn, 2006, Stem cells.

Selective evolutionary pressure from the tissue microenvironment drives tumor progression.

Meenhard Herlyn, M. Herlyn, K. Smalley, 2005, Seminars in cancer biology.

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

Keith T Flaherty, Meenhard Herlyn, K. Flaherty, 2006, Molecular Cancer Therapeutics.

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

Dimitris Kletsas, Vassilis G. Gorgoulis, Meenhard Herlyn, 2005, Nature.

Life ins't flat: Taking cancer biology to the next dimension

Keiran S. M. Smalley, Meenhard Herlyn, M. Herlyn, 2006, In Vitro Cellular & Developmental Biology - Animal.

FANTOM5 CAGE profiles of human and mouse samples

Hiroshi Tanaka, Geoffrey J Faulkner, Sarah Klein, 2017, Scientific Data.

Identification of a novel family of BRAF(V600E) inhibitors.

Peng Xie, Ronen Marmorstein, Meenhard Herlyn, 2012, Journal of medicinal chemistry.

Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models

Mark Morgan, Eric Brown, Meenhard Herlyn, 2016, Clinical Cancer Research.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Zhi Wei, Hongye Liu, Wei Huang, 2018, Cancer discovery.

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

Damien Kee, Xiaowei Xu, Meenhard Herlyn, 2010, Cancer cell.

Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options.

Meenhard Herlyn, M. Herlyn, A. Vultur, 2011, Cancer research.

A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth

Alexander Roesch, Devraj Basu, Meenhard Herlyn, 2010, Cell.

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.

Hieu T. Do, Meenhard Herlyn, David M. Wilson, 2006, Cancer research.

Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma

Zhi Wei, Yiling Lu, Gordon B Mills, 2018, EMBO molecular medicine.

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Kam Y. J. Zhang, James Tsai, Nikolas K. Haass, 2008, Proceedings of the National Academy of Sciences.

Regulation of Notch1 and Dll4 by Vascular Endothelial Growth Factor in Arterial Endothelial Cells: Implications for Modulating Arteriogenesis and Angiogenesis

Yan Li, Meenhard Herlyn, Ronald M. Fairman, 2003, Molecular and Cellular Biology.

Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization.

Cheng Luo, Weiliang Zhu, Mingyue Zheng, 2012, Organic & biomolecular chemistry.

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.

Jason W. Locasale, Sayan Mukherjee, Lorin Crawford, 2017, Cell reports.

BRAF and RAS mutations in human lung cancer and melanoma.

Richard Wooster, Helen Davies, Michael R Stratton, 2002, Cancer research.

Distinct MHC gene expression patterns during progression of melanoma

Joel Greshock, Xiaolu Yang, Meenhard Herlyn, 2009, Genes, chromosomes & cancer.

Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing Akt

Andrew D. Hamilton, Meenhard Herlyn, S. Nicosia, 2004, Cancer Research.

Direct conversion of mouse and human fibroblasts to functional melanocytes by defined factors

Zhi Wei, Xiaowei Xu, Wei Guo, 2014, Nature Communications.

Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression.

Chelsea C Pinnix, Min Xiao, Meenhard Herlyn, 2006, Cancer research.

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.

Gang Li, Kapaettu Satyamoorthy, Claus Garbe, 2005, Frontiers in bioscience : a journal and virtual library.

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas

Hong Wu, Johan Hansson, Alastair J. King, 2008, Molecular Cancer Therapeutics.

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

Eytan Ruppin, Zhi Wei, Noam Auslander, 2018, Nature Medicine.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Yiling Lu, Lauren E Haydu, Gordon B Mills, 2017, Cell reports.

Gene expression profiling of melanoma cells – searching the haystack

Meenhard Herlyn, M. Herlyn, P. Brafford, 2005, Journal of Translational Medicine.

The promise of 3D skin and melanoma cell bioprinting.

Meenhard Herlyn, Adina Vultur, Tim Schanstra, 2016, Melanoma research.

BRAF as a potential therapeutic target in melanoma and other malignancies.

Meenhard Herlyn, B. Weber, D. Tuveson, 2003, Cancer cell.

PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas

Zhi Wei, Gordon Mills, Yiling Lu, 2017, Nature.

Therapeutic destruction of insulin receptor substrates for cancer treatment.

Alexander Levitzki, Meenhard Herlyn, Efrat Flashner-Abramson, 2013, Cancer research.